Related references
Note: Only part of the references are listed.Polysomy of Chromosomes 1 and/or 19 Is Common and Associated With Less Favorable Clinical Outcome in Oligodendrogliomas: Fluorescent In Situ Hybridization Analysis of 84 Consecutive Cases
Andrea L. Wiens et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2012)
Co-Deletion of Chromosome 1p/19q and IDH1/2 Mutation in Glioma Subsets of Brain Tumors in Chinese Patients
Xiaohui Ren et al.
PLOS ONE (2012)
Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival Clinical article
Kaisorn L. Chaichana et al.
JOURNAL OF NEUROSURGERY (2011)
Polysomy for Chromosomes 1 and 19 Predicts Earlier Recurrence in Anaplastic Oligodendrogliomas with Concurrent 1p/19q Loss
Matija Snuderl et al.
CLINICAL CANCER RESEARCH (2009)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Panel review of anaplastic oligodendroglioma from European Organization for Research and Treatment of Cancer Trial 26951: Assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome
Johan M. Kros et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2007)
Temozolomide for low-grade gliomas - Predictive impact of 1p/19q loss on response and outcome
G. Kaloshi et al.
NEUROLOGY (2007)
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma
Robert B. Jenkins et al.
CANCER RESEARCH (2006)
Fluorescence in situ hybridization (FISH) on touch preparations: A reliable method for detecting loss of heterozygosity at 1p and 19q in oligodendroglial tumors
D Scheie et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2006)
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Epidemiology and molecular pathology of glioma
Judith A. Schwartzbaum et al.
NATURE CLINICAL PRACTICE NEUROLOGY (2006)
Chromosome 1p loss:: A favorable prognostic factor in low-grade gliomas
M Kujas et al.
ANNALS OF NEUROLOGY (2005)
Epidemiology and etiology of gliomas
H Ohgaki et al.
ACTA NEUROPATHOLOGICA (2005)
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions
K Hoang-Xuan et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
